Adalimumab (HUMIRA): A Review

August 2003 | Volume 2 | Issue 4 | Original Article | 375 | Copyright © August 2003

Noah Scheinfeld, MD,JD

Abstract
Adalimumab (HUMIRA™, Abbott Laboratories) is a new fully human TNF-? monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.